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journal homepage: http://www.elsevier.com/locate/crvasaThis issue of Cor et Vasa is focused on various aspects of
preventive cardiology. Preventive cardiology as a full-ﬂedged
subspecialty emerged in the 1960s and has became one of the
most important parts of cardiology. The country faced with the
ﬁrst epidemics of myocardial infarction was the USA. On the top
of 1960s, the majority of the American population, especially
middle-aged men, died from coronary heart disease (CHD). In
West European countries, the CHD epidemics culminated 10
years later to hit the Central European countries in the late
1980s. Despite the decreasing rates of CVD mortality in West
European countries at the end of the 20th century, seen also in
Poland and the Czech Republic – however, as the only two East
European nations – CVD has been the most common cause of
death over the last 50 years in the whole of Europe. At the
beginning of the 21st century, the CHD epidemics began to
spread eastward, to countries formerly making up the Soviet
Union (e.g., Moldavia, Ukraine, Russia, etc.) Today, about 4
million people, i.e. more than half of all those dying in Europe,
die from CVD (mainly CHD) each year [1].
The term cardiovascular disease (CVD) covers not only CHD
but also, other manifest complications of atherosclerosis such
as carotid artery stenosis, ischemic stroke, peripheral artery
disease, and other conditions. Atherosclerosis is the main
underlying cause of the most common CVDs and is blamed for
the biggest non-infectious disease epidemics at the end of the
20th and at the beginning of the 21st centuries worldwide.
Although major progress has been made in preventive,
diagnostic, and therapeutic strategies, CHD remains the most
common type of CVD. Coronary heart disease and ischemic
stroke are the most frequent causes for hospitalization
throughout Europe, including the Czech Republic. That is
why the European Society of Cardiology (ESC) and especially
the European Association for Cardiovascular Prevention and
Rehabilitation (EACPR) have consistently focused on preven-
tive approaches to CVD and developed, in conjunction with
other medical societies, the Joint Guidelines on CVD preven-
tion, with the latest one being published in the year 2012 [2]. A
short version of the guidelines included in this issue was
prepared by Renata Cifkova (Prague) – one of many authors of
the original English version.
Looking brieﬂy at the history of Czech preventive cardiolo-
gy, it would be fair to remember Klement Weber (one of the
founding fathers of Czech cardiology), who suggested theexistence of some predisposing factors for atherosclerosis as
early as 1928, i.e. 20 years before classic risk factors for CVD
and atherosclerosis were identiﬁed in the Framingham Heart
Study. Zdenek Reinis should be considered a pioneer of Czech
preventive cardiology; he designed the ﬁrst epidemiological
study of CHD in Northern Bohemia in 1950s and should be also
credited for launching the ﬁrst registry of myocardial infarc-
tion in Mlada Boleslav district [3]. Other Czech cardiologists
deserving mention here include Zdenek Fejfar, Jiri Fodor, and
Zbynek Pisa for their contribution to Czech preventive
cardiology, although some of them worked outside the
country. In the 1970s and 1980s preventive cardiology was
an integral part of the nationwide Cardiovascular program in
what was then Czechoslovakia [4]. The National Multifactorial
Primary Preventive Study of Myocardial Infarction and Strokes
coordinated by cardiologists at the Institute of Clinical and
Experimental Medicine (IKEM) represented the most impor-
tant research project in the ﬁeld of primary cardiovascular
prevention [5]. Despite these efforts, while the cardiovascular
risk proﬁle was clearly deﬁned for the Czech population, actual
clinical implementation of the most important preventive
recommendations based on the proﬁle into everyday practice
was most unsatisfactory at that time [6].
At the turn of 1980 and 1990s, the international MONICA
(Multinational MONItoring of trends and determinants in
CArdiovascular disease) project, initiated by the World Health
Organization, was launched to be carried out in 27 countries
across the world, including Czechoslovakia (participating
regions: Praha-vychod, Cheb, Benesov, Pardubice, Chrudim,
and Jindrichuv Hradec) [7]. Three independent 1% random
samples of males and females aged 25–64 years were enrolled
into the project in the years 1985, 1988, and 1992. The MONICA
study provided information about trends in CHD morbidity
and mortality over the 1985–1995 period. The results showed
downward trends in CVD incidence and mortality since the
1990s in the Czech population. Thanks to Renata Cifkova
(IKEM, Prague), epidemiological sentinel studies were later
designed to continue as a Czech Post-MONICA study now
including three additional districts (Pilsen, Litomerice, and
Kromeriz). These studies provided crucial data about the
current prevalence of both classic and new risk factors and
markers of CV risk, and long-term trends in mortality assessed
in a representative sample of the Czech population [8,9].
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Faculty in Pilsen (Charles University Prague) coordinated a
Czech multiregional interdisciplinary preventive project called
‘‘Research of complex management and prevention in
industrial populations’’ [10]. This line of research was intended
to investigate the standard of medical care and preventive
measures in chronic non-infectious diseases (mostly CVD)
affecting the Czech population. The epidemiological Pilsen
Longitudinal Intervention Studies PILS I, conducted in middle-
aged men [11], and PILS II [12] involving males and females
from an industrial population were included into this project.
It is necessary to mention another project called the Family
Protective Regimen; this program was the result of cooperation
of Pilsen cardiologists and pediatricians as the ﬁrst attempt to
keep children at high CV risk from early development of
atherosclerosis in families, where one or both parents
developed CHD at a relatively young age [13].
This idea was brought to life again later and as you will see
in the article written by our renowned pediatricians M.
Samanek and Z. Urbanova from Prague, a program CVD
prevention since childhood was ofﬁcially launched in the
Czech Republic in the year 1992. Since then, thanks of the two
above experts, most Czech pediatrics receive systematic
education and training in prevention of atherosclerosis and
its complications. General practitioners specializing in the
care and treatment of children currently perform preventive
examinations of children coming from high-risk families;
check the presence and status of standard risk factors and
educate the children (and also, their parents) about healthy
lifestyle, including principles of rational diet, importance of
regular physical activity, and avoidance of tobacco smoking
[14].
The ‘‘Velvet revolution’’ in 1989 paved the way to contacts
and cooperation with the ‘‘outer world’’ and new opportunities
for anyone with a keen interest in preventive cardiology.
Jaroslav Simon Sr. was the ﬁrst among Czech preventive
cardiologists to become a member of the ESC Working Group
(WG) on Prevention and Epidemiology of CVD (later trans-
formed into the European Association for Cardiovascular
Prevention and Rehabilitation, EACPR). The scientiﬁc meeting
of this ESC WG took place on May 22–25, 1996 in Pilsen; the ﬁrst
time in a former East Block country. The meeting was
organized by J. Simon Sr. and his team at the 2nd Medical
Department and the Medical Faculty in Pilsen. J. Simon Sr. was
also involved in the development of the EUROASPIRE
(European Action on Secondary and Primary Prevention by
Intervention to Reduce Events) study design.
The main aim of the EUROASPIRE (EA) surveys was to
evaluate the standard of implementation of the preceding
European Guidelines on CVD prevention. The ﬁrst EA survey
was conducted between 1995 and 1996 in nine countries,
followed by a second independent survey (1999–2000) involv-
ing 15 countries. Both of these surveys showed high rates of
modiﬁable CV risk factors in patients with stable CHD in all
participating countries, as well as failure to achieve the
recommended targets for all established risk factors in all
patients. The third EA survey was performed in 2006–2007 in 22
countries; its results show that, despite similarities in
medication exposure, women are less likely than men to
achieve blood pressure, LDL-cholesterol and glycosylatedhemoglobin (HbA1c) targets after a coronary event. This gap
did not appear to narrow between 1994 and 2007. The critical
role of lifestyle, not only in the primary prevention of CVD but
also, in secondary prevention, even within a few months of an
acute coronary event, was demonstrated in the third EA
survey. Adverse lifestyle trends among coronary patients such
as higher smoking rates among younger females, increasing
obesity and central obesity, and higher incidence of diabetes
[15]. David Wood (London), the principal investigator of EAs,
commented these results as a big disappointment; despite the
existence of clear, evidence-based guidelines, their implemen-
tation in routine clinical care was considered absolutely
unsatisfactory. Number of countries involved into the EA
surveys continues to increase, and the fourth EA survey (2012–
2013) joined by a total of 25 countries. The Czech centers
(Pilsen and Prague) have participated in all these four surveys.
A comparison of established and other risk factors control in
all four Czech editions of the EA surveys is presented in this
issue (papers written by O. Mayer Jr., J. Bruthans as ﬁrst
authors). It is generally accepted that there is still much room
not only in the Czech Republic but also, throughout Europe
countries to raise the standards of preventive cardiology.
Another issue attracting considerable attention over the
past 20 years is residual cardiovascular risk in patients at high
and very high CV risk. Residual risk can be deﬁned as
persistence of CV risk due to inadequately treated established
risk factors. There are a high prevalence of CHD patients not
achieving the recommended target levels of total and/or LDL-
cholesterol and casual levels of blood pressure. One of the
reasons may be that many patients simply fail to comply with
the recommended changes in their lifestyle and also with
drugs taking. On the other hand, residual vascular risk may be
due to other emerging risk factors, e.g., factors associated with
the metabolic syndrome and type 2 diabetes mellitus (T2DM).
Additional evidence suggests that a major contributor to
residual vascular risk is atherogenic dyslipidemia (elevated
triglycerides and low HDL-cholesterol) [16]. Triglyceride levels
are considered a marker of triglyceride-rich lipoproteins (TRLs)
and their remnants, which are highly atherogenic. It is
particularly remnant cholesterol that plays a causative role
in CHD and represents an important factor in residual CV risk
[17]. The EPIC Norfolk study clearly demonstrated that the
non-LDL components of the lipid proﬁle are major contributors
to residual vascular risk, this applies even to individuals
achieving their LDL-cholesterol target values [18].
A comparative analysis of Czech samples included in the EA
I–IV surveys identiﬁed major markers of residual CV risk,
particularly a high atherogenic plasma index, found consis-
tently in the same number of Czech CVD patients over the past
16 years. These results show the big potential of preventive
approaches in patients with chronic stable CVD treated by
statins, renin–angiotensin system inhibitors, beta-blockers, and
antiplatelet medications. All markers of residual vascular risk
are signiﬁcantly more prevalent in patients with T2DM, with the
prevalence rising steeply over the above period of time (see
paper written by Nussbaumnerova et al.). Diabetic patients are
additionally at high risk of developing microvascular complica-
tions (retinopathy, nephropathy, and neuropathy), not ade-
quately controlled by standard therapy including statin-only
therapy. It is generally recognized that fenoﬁbrate – alone or in
c o r e t v a s a 5 6 ( 2 0 1 4 ) e 8 7 – e 9 0 e89combination with statin therapy – leads to signiﬁcant reduc-
tions of the rate of ﬁrst leg amputation in diabetics and reduces
the development of diabetic retinopathy and nephropathy
[19,20].
The importance of combination lipid-lowering therapy in
the management of high-risk patients (statin with fenoﬁbrate
and statin with ezetimibe) is highlighted in another two papers
in this issue of Cor et Vasa (by Hana Rosolova and Michal
Vrablik as the ﬁrst authors). The papers show the current
trends not only in the successful management of dyslipidemia
but also, a strategy for reducing residual vascular risk among
patients receiving standard therapy.
Patients with obstructive sleep apnea (OSA) experience
episodes of obstruction of the upper airway during sleep
leading to increase of excessive daytime sleepiness as well as
many cardiovascular and metabolic disorders. Approximately
4% of middle-aged males and 2% of middle-aged females have
OSA deﬁned as an apnea hypopnea index (AHI)  5 [21]. The
study presented in this issue of Cor et Vasa has demonstrated a
high prevalence of masked and nocturnal hypertension in
patients with OSA, which can considerably increase CVD risk
in these patients (Sova). A recently published Spanish study
demonstrated that the prevalence of metabolic syndrome in
patients with OSA is high and increases with the severity of
OSA. That is why it is very important to search, in OSA
patients, for the presence of metabolic syndrome or its
components, and to start early intervention to reduce their
high CV morbidity and mortality [22].
Lifestyle is a modiﬁable factor that can quite easily help
reduce CV and metabolic risk in healthy subjects, i.e., in
primary prevention of CVD and T2DM, as well as in patients
with CVD or T2DM, i.e., in secondary prevention of CVD or
prevention of microvascular complications. Lifestyle and
consequently, risk factors have been consistently changing
over time. Fifty years ago, arterial hypertension, high
cholesterol levels, and smoking were associated with high-
fat and too salty diet, and an increasing prevalence of tobacco
addiction. While those risk factors continue to be the
established risk factors for CVD, sedentary lifestyle and intake
of high-energy diet (sweet and fatty) emerge as relatively novel
widespread woes resulting in overweight, obesity, metabolic
syndrome and T2DM. After all, the Czech Republic belongs to
nations with the highest prevalence of T2DM among European
countries!
Numerous earlier studies have shown that especially
visceral fat accumulation is a link to insulin resistance and
development of the cluster of emerging hemodynamic (high
blood pressure and heart rate) and metabolic risk factors
(atherogenic dyslipidemia, glucose metabolism disturbances),
that occur very often together thus multiplying the risk for
CVD and T2DM. The relative risk for CV events in subjects with
metabolic syndrome and even more so in diabetic patients is
signiﬁcantly increased, to 2–3 times in males and 3–4 times in
females, compared with individuals without metabolic syn-
drome and without T2DM. Patients with metabolic syndrome
have 5 times higher risk for T2DM in comparison with
individuals without metabolic syndrome. This explains why
the condition of patients with metabolic syndrome, impaired
fasting glucose (plasma glucose 5.6–6.9 mmol/l) and impaired
glucose tolerance (oral glucose tolerance test – glucose in the2nd hour: 7.8–11.0 mmol/l) is referred to as prediabetes. As the
prediabetic stages are modiﬁable, they can be reversed by
healthy lifestyle (reduction of energy intake, eating healthy
food, regular physical activity, and non-smoking). Cardiome-
tabolic risk, prediabetes, and management of CVD in patients
with T2 DM are the main topics for the last guidelines
developed by European cardiologists and diabetes experts in
2013 [23]. See a short version of these guidelines included in
this issue (Rosolova et al.).
Atherosclerosis and its complications (especially CVD) or
T2DM and also, many types of cancer are preventable diseases,
i.e., a healthy lifestyle can prevent their development. A
balanced rational diet, regular physical activity, avoidance of
smoking, and unnecessary stress are capable of suppressing or
minimizing genetic predispositions for those polygenic dis-
eases. To live a healthy life and to care of one's good health is
closely associated with wellbeing. This approach is also less
expensive than leading an unhealthy life and getting ill
(developing high blood pressure, dyslipidemia, obesity and
later, atherosclerotic vascular complications, especially CVD
or T2DM) progressive to heart and kidney failure. Those
diseases are associated with the need to use medicaments, to
undergo numerous interventions and procedures or to be
hospitalized. All this is associated not only with feeling unwell
and ﬁnancial burden for the patient as well as society at large
but most importantly, with a shorter lifespan. Why do the
majority people actually like to do more unhealthy things than
healthy things? This question is yet to be answered.
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